Advertisement

Topics

Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD

10:30 EST 10 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for dasotraline, a novel dual-acting dopamine and norepineph...

Other Sources for this Article

Sunovion Pharmaceuticals Inc.
Kristina Coppola, 508-787-4368
Associate Director, Portfolio Communications
kristina.coppola@sunovion.com

NEXT ARTICLE

More From BioPortfolio on "Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...